SSG
ZNTL icon

Summit Securities Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Summit Securities Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49K Buy
+514
New +$2.05K ﹤0.01% 1078
2024
Q4 		– Sell
-145
Closed -$1K – 944
2024
Q3 		$1K Buy
+145
New +$527 ﹤0.01% 527

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Summit Securities Group's ZNTL Position: Q2 2026 in Review

Summit Securities Group opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 514 shares worth $2.49K. The stake represents ﹤0.01% of the portfolio and ranks #1078 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in ZNTL as recently as Q3 2024.

Summit Securities Group first reported a position in ZNTL in Q3 2024 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Summit Securities Group held 514 shares of Zentalis Pharmaceuticals worth $2.49K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Summit Securities Group position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #1078 holding.
  • Summit Securities Group first reported a position in Zentalis Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.